Get started

Biotech

$MIRM bear proof 👁‍🗨 *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management My team entered Mirum Pharmaceuticals $MIRM today at $25 per share. Our take profit is $30. We also have a stop less set at $24 OUR ENTRY: $25 FIRST TAKE PROFIT: $30 STOP LOSS: $24 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
4
$NRX.V Outpaces Biotech Peers Following TSX.V Listing The biotech sector is presenting exciting opportunities for investors despite the broader downturn in global equity markets. Many of the best biotech companies and ETFs have both strong drug candidate pipelines in the works as well as winning drugs and therapeutic products already on the market. The COVID-19 pandemic has proven and created massive opportunities for the biotechnology sector as a whole, particularly so around innovative players that are developing therapeutic solutions with disruptive potential. One new player to the field is Nurexone Biologic (NRX.V), a new listee on the TSXV exchange that is redefining exosome therapeutics for application to traumatic brain and spinal cord injuries. It is creating a platform for biologically-guided ExoTherapy that will be administered minimally invasively to patients who have had catastrophic spinal cord injuries. Since July 15th, NRX +26% as it attracts new investors and institutional players begin to trade the equity. In comparison, the TSX/SPX composite index charted 6% gains, indicating that NRX far outperformed the market baseline over the course of the summer rally. Relative to sectoral ETFs, Nurexone is also trading strong. IBBQ is +6.9% and XBI +6% over the same timeframe NRX is +26%; it is important to note that over this period, the company did not release any price sensitive announcements that would otherwise account for its significant bullish price movement. Further, exosome-based equities are one area of the wider biotech industry that has continuously traded robustly despite subpar performance for equity markets this year. Sectoral competitors are mixed bag, with KMPH +4.8% while APTO is down 4.4%. Kodiak Biosciences (KOD) jumped 20%, though it still lags behind NRX's 26% increase. This indicates that as exosome therapeutic developers struggle to maintain forward momentum amidst the backdrop of a challenging macroeconomic landscape, NRX is outperforming both sectoral ETFs and direct competitors. Though its a newby to capital markets, so far Nurexone is standing out as the bullish outlier with LT potential.
TSXV:NRX
by BiotechBrandon
BCDA Short AnalysisBCDA has an upcoming CardiAMP Heart Failure DSMB review on the 30th of this month (August). Although the treatment indicated no significant safety concerns, I have reasonable doubt that this won't go through to be accepted by the FDA; the Phase III to NDA/BLA is about a 58.1% chance, the NDA/BLA to Approval is a 85.3% chance, and then the Phase I to Approval is a 9.6% chance. BioCardia has 6 treatments that are under trials and the CardiAMP Ischemic Heart Failure treatment is the closest to approval. If this treatment doesn't get approved, everything will rip apart and the market for this will plunge. Chart-wise, there is a consistent downtrend on the 1-Day mark. If you are putting a short position on this, I highly recommend you to have buy-stop orders.
NASDAQ:BCDAShort
by spamgod
1
MNMD Biotech Penny Stock SHORT SETUPNASDAQ:MNMD Yj This stock had a quick response to good earnings and it is now at resistance with the RSI swing indicator printing a Sell Signal. The MACD, a lagging indicator, shows the signal above the histogram without a K / D cross not yet started. I would like to take a short trade setting a stop loss above the resistance zone and targeting 10% to the POC line of the volume profile sitting above the support zone. Please comment and offer your opinion. 3
NASDAQ:MNMDShort
by AwesomeAvani
8
LABU 3X Leverage BIOTECHNOLOGY a potential Recession playLABU a 3x leveraged EFT in the biotechnology sector has diverse holdings. My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market. Here I chart LABU / QQQ ratio to determine relative strength. On this weekly chart, the ratio and so relative strength are at more than a 52 week low. The MACD indicator shows the MACD and signal line ascending and below the histogram.; moreover the MACD in green is running above the signal line. This favors a trend reversal. All in all, this seems to be a setup for a long swing trade or investment. I will take a trade in a call option with a strike 50% higher than current price as I see a potential for a large percentage gain for LABU. The diversity of the ETF will serve to mitigate some of the risk. A stop loss will be 1% below current price with an expectation of more than a 50 % return in the remainder of the calendar year but far more in the case of the call option scenario
AMEX:LABULong
by AwesomeAvani
LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX LXRX has gained over 100% in the past month However it appears to be forming a double top in a potential short trade setup on the two hour chart. The K/D crossover on the hot RSI oscillator provides confirmation. Short Sale Volume is rising in the past two days. Findamentals - LXRX has a new medication for heart failure a common medical problem with a massive market It recently launched a public offering to raise capital to fund general operations and in doing so diluted the share holders. The good news is it is unlikely to do another in the near term. An entry would be at the current price with a stop loss above the highest volume bar on the profile. The first target is the POC of the volume profile about a 15% price drop . The second target is the pivot low on August 1st for another 15% drop. Taking of 1/2 at each target yields an expected 23% return over a period of about 5 trading days since drops are faster than rises. The call options of mid September have low volumes so I will not consider them.
NASDAQ:LXRXShort
by AwesomeAvani
UBX ( NASDAQ BIOTECH PENNY) crushes earnings and news catalystNASDAQ:UBX and rises over 100 % in premarket, Has a new product for macular degeneration, a widespread medical problem affecting vision in the elderly which is increasing in incidence. The earning beat was significant. Chart demonstrates the uptrend and midrange RSI but does not show today's premarket. 40 % rise in the week leading up to earnings and now parabolic. doubling overnight. * Get in the party now, don't be late. If you are late stay home" ( not a recommendation to buy only education)
NASDAQ:UBXLong
by AwesomeAvani
2
Biotech: textbook bullish continuation pattern breakoutBiotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process. IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through. Keep an eye on the old Feb/Apr highs around 135 which seems like the next target in this uptrend.
NASDAQ:IBB
by EvanMedeiros
1